NCT01865617View on ClinicalTrials.gov

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

May 22, 2013

Primary Completion Date

March 26, 2021

Study Completion Date

March 26, 2021

Conditions
CD19-Positive Neoplastic Cells PresentRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Mantle Cell LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Chronic Lymphocytic LeukemiaRefractory Diffuse Large B-Cell LymphomaRefractory Mantle Cell LymphomaRefractory Non-Hodgkin LymphomaRefractory Small Lymphocytic Lymphoma
Interventions
BIOLOGICAL

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT01865617 - Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter